Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mEOC first-line chemotherapy trial in mucinous epithelial ovarian cancer
2008-000837-23Phase 3Completed
- Sponsor
- University College London
- Start
- Aug 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, paclitaxel, oxaliplatin, capecitabine and bevacizumab in ovarian cancer (4 arms), sponsored by University College London. Primary endpoint: Overall survival. Started Aug 2008; status: completed.
02
Drugs
carboplatinpaclitaxeloxaliplatincapecitabinebevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2008-000837-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000837-23.